Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2026 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical...
02. April 2026 08:00 ET | Quelle: VisionWave Holdings, Inc.

VisionWave Converts Latin American Government Engagement into Initial Defense Order

WEST HOLLYWOOD, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (NASDAQ: VWAV) (“VisionWave” or the “Company”), a next-generation defense technology and advanced sensing...
02. April 2026 08:00 ET | Quelle: LifeVantage Corporation

LifeVantage Announces Expansion of its European Footprint with Market Opening in Portugal

SALT LAKE CITY, April 02, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the...
02. April 2026 08:00 ET | Quelle: Kustomer

Kustomer Launches “Kustomer AI - Signals” to Turn Customer Intelligence Into Real-Time Action Across the CX Stack

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Kustomer, the AI customer experience platform, today unveiled “Kustomer AI - Signals”, a new AI capability within AI for Reps that extends Kustomer's...
02. April 2026 07:54 ET | Quelle: WOLFSON BRANDS (UK) LIMITED

Strongest Phentermine Alternatives For Weight Loss 2026: Over The Counter - Lunched by Wolfson brands How To Take Phentermine 37.5 Diet Pills for Best Results?

New York City, April 02, 2026 (GLOBE NEWSWIRE) -- Wolfson brands launch the strongest Phentermine Alternatives in 2026. To unlock the full potential of Phentermine in your weight loss journey,...
02. April 2026 07:43 ET | Quelle: Yukon Metals Corp.

Yukon Metals Intersects 11.7 g/t Gold Within Extensive Vein System in First Drill Program and Expands Land Package at Star River Property

YUKON METALS INTERSECTS 11.7 G/T GOLD WITHIN EXTENSIVE VEIN SYSTEM IN FIRST DRILL PROGRAM AND EXPANDS LAND PACKAGE AT STAR RIVER PROPERTY
02. April 2026 07:30 ET | Quelle: Annovis Bio Inc.

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
02. April 2026 07:30 ET | Quelle: Context Therapeutics Inc.

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,...
02. April 2026 07:30 ET | Quelle: MiNK Therapeutics

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...
02. April 2026 07:01 ET | Quelle: Adagene Inc.

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide...

Vorherige Seite

Nächste Seite